New Zealand Government Authorizes LCT’ Diabecell Clinical Trial

Living Cell Technologies (LCT) has announced that New Zealand Ministery of Health has authorized LCT’ New Zealand phase I/IIa clinical trial of Diabecell, for insulin dependent diabetes.

The authorization confirms the conditions announced on June 19, 2009. One condition of the new authorization limits participation in the trial, to patients with poorly controlled (brittle) diabetes. The remaining conditions are procedural rather than substantive in nature, and LCT and the Middlemore Hospital clinical team have requested the Regional Ethics Committee to accept the changes required by the Minister.

Dr. Paul Tan, CEO of LCT, said: “We are pleased that the conditions have been finalized and LCT looks forward to commencing the trial within the next two months with the acceptance of the changes by the Ethics Committee.”